Abstract C42: Safety and preliminary efficacy results of a first-in-human phase I study of the novel cancer stem cell (CSC) targeting antibody brontictuzumab (OMP-52M51, anti-Notch1) administered intravenously to patients with certain advanced solid tumors

2015 ◽  
Author(s):  
Pamela Munster ◽  
S. Gail Eckhardt ◽  
Amita Patnaik ◽  
Anthony F. Shields ◽  
Anthony W. Tolcher ◽  
...  
Keyword(s):  
Stem Cell ◽  
Cancer Stem Cell ◽  
Phase I ◽  
Solid Tumors ◽  
Phase I Study ◽  
Advanced Solid Tumors ◽  
The Novel

Dose escalation stage of a first-in-class phase I study of the novel oral ERK 1/2 kinase inhibitor BVD-523 (ulixertinib) in patients with advanced solid tumors.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 2506-2506 ◽  
Author(s):  
Jeffrey R. Infante ◽  
Filip Janku ◽  
Anthony W. Tolcher ◽  
Manish R. Patel ◽  
Ryan J. Sullivan ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Dose Escalation ◽  
Phase I Study ◽  
Kinase Inhibitor ◽  
Advanced Solid Tumors ◽  
The Novel

Phase I study of the novel taxane CT-2103 in patients with advanced solid tumors

2005 ◽  
Vol 55 (5) ◽  
pp. 497-501 ◽  
Author(s):  
Maria Luisa Veronese ◽  
Keith Flaherty ◽  
Amy Kramer ◽  
Barbara A. Konkle ◽  
Mark Morgan ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Phase I Study ◽  
Advanced Solid Tumors ◽  
The Novel

A phase I study of the novel, third generation epothilone ZK-EPO in patients with advanced solid tumors

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 2051-2051 ◽  
Author(s):  
P. Schmid ◽  
P. Kiewe ◽  
D. Kuehnhardt ◽  
A. Korfel ◽  
S. Lindemann ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Phase I Study ◽  
Third Generation ◽  
Advanced Solid Tumors ◽  
The Novel

A phase I extension study of BBI608, a first-in-class cancer stem cell (CSC) inhibitor, in patients with advanced solid tumors.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 2546-2546 ◽  
Author(s):  
Derek J. Jonker ◽  
Joe Stephenson ◽  
William Jeffery Edenfield ◽  
Jeffrey G. Supko ◽  
Youzhi Li ◽  
...  
Keyword(s):  
Stem Cell ◽  
Cancer Stem Cell ◽  
Phase I ◽  
Solid Tumors ◽  
Extension Study ◽  
Advanced Solid Tumors

scholarly journals A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors

2017 ◽  
Vol 23 (24) ◽  
pp. 7490-7497 ◽  
Author(s):  
Antonio Jimeno ◽  
Michael Gordon ◽  
Rashmi Chugh ◽  
Wells Messersmith ◽  
David Mendelson ◽  
...  
Keyword(s):  
Stem Cell ◽  
Phase I ◽  
Solid Tumors ◽  
Phase I Study ◽  
Advanced Solid Tumors ◽  
Decoy Receptor ◽  
Wnt Ligands
Sign in / Sign up

Export Citation Format

Share Document